Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis
| Autor: | Fiona Patrick, Dimosthenis Tsapekos, Anthony J. Cleare, Rachael W. Taylor, Lindsey Marwood, Ben Carter, Rebecca Strawbridge, Viktoriya L Nikolova, Allan H. Young, Borwin Bandelow, Tim Mantingh, Valeria de Angel |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Psychopharmacology Psychological intervention Augmentation Placebo Depressive Disorder Treatment-Resistant Internal medicine medicine Humans Depression (differential diagnoses) business.industry medicine.disease Antidepressive Agents Psychological Therapy Psychotherapy Psychiatry and Mental health Treatment Outcome Pharmacological interventions Meta-analysis Pill Aripiprazole Systematic Review Treatment-resistant depression business medicine.drug |
| Zdroj: | Strawbridge, R, Carter, B, Marwood, L, Bandelow, B, Tsapekos, D, Nikolova, V L, Taylor, R, Mantingh, T, De Angel, V, Patrick, F, Cleare, A J & Young, A H 2018, ' Augmentation therapies for treatment-resistant depression : systematic review and meta-analysis ', British Journal of Psychiatry, vol. 214, no. 1, pp. 42-51 . https://doi.org/10.1192/bjp.2018.233 |
| ISSN: | 1472-1465 0007-1250 |
| Popis: | BackgroundDepression is considered to have the highest disability burden of all conditions. Although treatment-resistant depression (TRD) is a key contributor to that burden, there is little understanding of the best treatment approaches for it and specifically the effectiveness of available augmentation approaches.AimsWe conducted a systematic review and meta-analysis to search and quantify the evidence of psychological and pharmacological augmentation interventions for TRD.MethodParticipants with TRD (defined as insufficient response to at least two antidepressants) were randomised to at least one augmentation treatment in the trial. Pre-post analysis assessed treatment effectiveness, providing an effect size (ES) independent of comparator interventions.ResultsOf 28 trials, 3 investigated psychological treatments and 25 examined pharmacological interventions. Pre-post analyses demonstratedN-methyl-d-aspartate-targeting drugs to have the highest ES (ES = 1.48, 95% CI 1.25–1.71). Other than aripiprazole (four studies, ES = 1.33, 95% CI 1.23–1.44) and lithium (three studies, ES = 1.00, 95% CI 0.81–1.20), treatments were each investigated in less than three studies. Overall, pharmacological (ES = 1.19, 95% CI 1.08–1.30) and psychological (ES = 1.43, 95% CI 0.50–2.36) therapies yielded higher ESs than pill placebo (ES = 0.78, 95% CI 0.66–0.91) and psychological control (ES = 0.94, 95% CI 0.36–1.52).ConclusionsDespite being used widely in clinical practice, the evidence for augmentation treatments in TRD is sparse. Although pre-post meta-analyses are limited by the absence of direct comparison, this work finds promising evidence across treatment modalities.Declaration of interestIn the past 3 years, A.H.Y. received honoraria for speaking from AstraZeneca, Lundbeck, Eli Lilly and Sunovion; honoraria for consulting from Allergan, Livanova and Lundbeck, Sunovion and Janssen; and research grant support from Janssen. In the past 3 years, A.J.C. received honoraria for speaking from AstraZeneca and Lundbeck; honoraria for consulting with Allergan, Janssen, Livanova, Lundbeck and Sandoz; support for conference attendance from Janssen; and research grant support from Lundbeck. B.B. has recently been (soon to be) on the speakers/advisory board for Hexal, Lilly, Lundbeck, Mundipharma, Pfizer, and Servier. No other conflicts of interest. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|